JAK Inhibition in Ulcerative Colitis

The treatment for Ulcerative Colitis (UC) aims to achieve and maintain remission and is usually lifelong and expensive. Current available medications are unable to break the cycle of chronic inflammation, and still a significant proportion of patients will fail to respond (primary non-response) or lose response over time (secondary non-response). There is now growing evidence that there is substantial interpatient variation in the composition of the inflammation associated network of immune cells. A deeper knowledge of the patient's alterations in the mucosal immune response would help identify key drivers of inflammation and select the appropriate therapy. By analyzing the changes in the composition of immune cells induced by Janus Kinase (JAK) inhibition, we aim to obtain a better insight into the mechanistic effects of JAK inhibition and the downstream effects. These mechanistic insights are needed to identifying potential responders and non-responders in the future.

NCT Number	NCT05456412
Lead Sponsor	Leiden University Medical Center Collaborators: Lakefront Biotherapeutics NV
Conditions	Colitis, Ulcerative
Enrollment	60 participants
Start Date	2022-12-20
Primary Completion	2025-09 (estimated)
Study Completion	2026-09 (estimated)
Updated on ClinicalTrials.gov	2022-12-22